PRF Technologies Ltd.

Going-concern micro-cap pharma whose lead Phase 3 (PRF-110) missed its primary endpoint, now pivoting to an early-stage ocular asset and an unrelated solar business.

Strengths

• Pivot asset OcuRing-K showed a clean Phase 1 safety profile and is advancing toward Phase 2
• Reported current ratio 1.78 and a nominal multi-quarter cash-runway metric

Risks

• Explicit going-concern doubt with only ~$4.1M cash and an accumulated deficit of $61.3M
• Lead Phase 3 PRF-110 failed its 72-hour primary endpoint — a severe, materially negative readout
• Extreme negative margins, identified material weakness, and Nasdaq delisting risk

Notable findings

• Going concernThe report of our independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern
• Net lossNet loss (net margin -29541.2%)
• Cash burnNegative free cash flow (-4.0M)
• Material weakness● We have identified a material weakness in our internal control over financial reporting